SCHEMBL6773500

SCHEMBL6773500

CC1(c2cc3nnc(-c4ccc(F)cc4F)n3nc2Cl)CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.39
PIM1 P11309 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
HSD17B10 Q99714 2/20 0.33
CNR1 P21554 1/20 0.32
HASPIN Q8TF76 1/20 0.32
HSD11B1 P28845 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAP4K4 O95819 1/20 0.32
EGFR P00533 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK1D P48730 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6991455 0.77 KDM4E (0.42) PIM1GABRA1GABRG2GABRB3GABRA3
SCHEMBL6773152 0.77 GABRG2 (0.61) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6779109 0.77 GABRG2 (0.43) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL2655376 0.76 HSD17B10 (0.43) MAPK14PIM1HSD17B10CNR1MAP4K4
SCHEMBL6773657 0.76 GABRG2 (0.35) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL341882 0.76 GABRG2 (0.62) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL341950 0.76 GABRG2 (0.44) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL341951 0.74 GABRG2 (0.36) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL6772385 0.74 GABRG2 (0.62) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL341566 0.72 GABRG2 (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 MAPK14 2354/4885PIM1 4661/4885GABRA1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.